RxDoctor Payments Data

Kyung Kim, MD

Medical Oncology · Sheridan, WYNPI 1457391773

Payments from drug & device makers

$1,372in general payments, 2019–2025

Across 23 payments — averaging $59.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$379
  • Sanofi-aventis U.S. LLC$199
  • AstraZeneca$150
  • Johnson & Johnson$113
  • Clovis Oncology, Inc.$100
  • Amgen$95
  • plus $335 from 8 others

What the payments were for

  • Food & beverage$43632%
  • Education$93568%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few medical oncology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$698,863
Medicare patients
282
Services billed
36,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate28$461,056
CalquenceAcalabrutinib Maleate16$245,010
RevlimidLenalidomide13$209,121
ImbruvicaIbrutinib12$200,219
StivargaRegorafenib11$118,388
EliquisApixaban14$13,513
Letrozole90$2,187
Abiraterone Acetate15$1,729
Anastrozole18$917
Prochlorperazine Maleate42$562
Tamoxifen Citrate12$452
Dexamethasone19$396
Hydroxyurea11$358
Acyclovir30$227
Ondansetron OdtOndansetron43$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$150$706,06644 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$53$200,21912 claims
PfizerEliquis$80$13,51314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Sheridan

Where these figures come from

Is this you, or does something look wrong? →